Linda Rogers is a Respiratory physician affiliated with Mount Sinai Health System. OpenAlex indexes 116 publications with 4,102 citations (h-index 26); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
10 E 102nd St
New York, NY 100296030
Telephone
212-241-5656Registry record last updated 27 Feb 2019.
Clinical trials
- Real World and Genomic Data Based Asthma Insight Through Network Analysis
Sponsor: Icahn School of Medicine at Mount Sinai
- Long-acting Beta Agonist Step Down Study
Sponsor: Johns Hopkins University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year202510 payments
- SANOFI US SERVICES INC.Program year20251 payment
- GlaxoSmithKline, LLC.Program year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
77.6%Corticosteroid44.3%Trelegy Ellipta45%Fluticasone Propionate18%Breo Ellipta15%Budesonide-Formoterol Fumarate9%Dulera4%Breztri Aerosphere4%Arnuity Ellipta3%Symbicort2%Part D<11 patientsbeta2-Adrenergic Agonist22.2%Albuterol Sulfate Hfa83%Ventolin Hfa14%Airsupra4%Part D<11 patients+ 6 more classes in this area
Dermatology
10.1%Interleukin-4 Receptor alpha Antagonist10.1%Dupixent Pen88%Dupixent Syringe12%Part D<11 patientsMetabolism & gastrointestinal
7.9%Corticosteroid7.9%Prednisone100%Part D≥64 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Consensus summary on the definition of asthma remission
Journal of Allergy and Clinical Immunology
2025 - A critical look at the lexicon, parameters, and limitations of asthma remission definitions
Journal of Allergy and Clinical Immunology
2025 - The SARS-CoV-2 pandemic and asthma: What we have learned and what is still unknown
Journal of Allergy and Clinical Immunology
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Robert Desnick, PhD, MD
Mount Sinai Health System
Mathew Williams, MD
Mount Sinai Health System
Ashutosh Tewari, MD
Mount Sinai Health System
Sahil Khera, MD, MPH
Mount Sinai Health System
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”